The Journal of Industry and Technology

Industrial Analytical Instrumentation

Euro Technology

Serving industry for over 36 years
Three leading magazines for key executives,  engineers, universities,
manufacturers, laboratory technicians, scientists, and research establishments

Life sciences and clinical instrumentation

BIOTRONIK initiates study validating safe and efficient
in-office insertion of BioMonitor 2 Cardiac Monitor

BioInsight Study to Show Safety, Feasibility of In-Office Procedure, with Data Assessing Time and Resources in Comparison to Traditional Hospital Settings.

BIOTRONIK recently announced the first patients enrolled in the BioInsight clinical study. The study evaluates the safety and feasibility of performing the minimally invasive BioMonitor 2 insertion procedure in an office setting.

BioMonitor 2 is an insertable cardiac remote monitor with ProMRI® technology that is placed underneath a patient's skin to help physicians accurately detect and diagnose atrial fibrillation and syncope (fainting). Atrial fibrillation is a leading cause of stroke and heart failure. BioMonitor 2 provides the highest signal amplitude on the market, which leads to excellent sensitivity for improved reporting accuracy. The device can also be used to monitor atrial fibrillation in patients who have undergone ablation procedures. More than 2,000 BioMonitor 2 devices have been sold in the US since FDA approval in April 2016.

"One of the benefits of BioMonitor 2 is the ease of the insertion procedure, which typically only takes a few minutes," commented Dr. Raul Weiss, cardiologist at Ohio State University. "In-office procedures can reduce patient's and physician's time, increase access to the device and reduce cost burdens for healthcare systems. Early insertion will likely also reduce the time needed for a conclusive diagnosis."

The BioInsight study is a multi-center, prospective, non-randomized post-market study. Participants will receive BIOTRONIK's BioMonitor 2 via in-office insertion and will be evaluated for 90 days to monitor for any potential adverse events, including infection and bleeding.

"BioMonitor 2 has been rapidly adopted by physicians, becoming a trusted, reliable solution to monitor for cardiac arrhythmias," said Marlou Janssen, President, BIOTRONIK, Inc. "There is a significant need for BioMonitor 2, and we want to ensure our physicians have the utmost confidence in their ability to deliver efficient patient care. The BioInsight study will assure physicians and patients that performing the insertion procedure in an office setting safely and effectively improves access to this critical diagnostic tool."

The BioInsight study is expected to be completed in the third quarter of 2017. Additional details about BioMonitor 2 are available on BIOTRONIK's website.
For further information, view website: or e-mail: 
Refer to page 402

Quick page links - Display rates - Features - Magazine profile - Home page - Company index - Page 276

Industrial and Technological Publications
Leading the way in on-line magazine publishing
The Journal of Industry and Technology - Euro Technology - Industrial Analytical Instrumentation
Title registered in London 1978. Registration number 2334966

Twitter: - Twitter: - Twitter: www,
Google+: Linkedin:
Google+:  Google+: /+Industrialanalyticalinstrumentation21IA
Follow on Facebook: